Martin Rose co-founded TETRAPHARM in 2018 with Jesper Breum. Rose holds an MSc degree and spent more than 15 years in various senior positions within the pharmaceutical industry prior to founding the company.
Career History
- Chief Executive Officer & Co-founder, TETRAPHARM (2018–2026)
- Senior positions at FUJIFILM Diosynth Biotechnologies
- Senior positions at Biogen
- Senior positions at Novo Nordisk
TETRAPHARM specializes in developing pharmaceutical drugs targeting the central nervous system and immune system, with a strong foundation in biotech and CNS. The company maintains a promising R&D pipeline with lead candidates targeting chronic pain, Alzheimer's and obesity, alongside tailored end-to-end CDMO services.
What Martin Rose could bring to his new ventures: With 15+ years in senior pharmaceutical leadership across major organizations (Novo Nordisk, Biogen, FUJIFILM Diosynth), followed by eight years building TETRAPHARM from inception to a clinical-stage biopharmaceutical company with approved products and CDMO services, Rose possesses deep expertise in drug development, manufacturing scale-up, regulatory navigation, and commercialization. He and co-founder Breum remain shareholders in TETRAPHARM while pursuing new biotech ventures together, indicating their intention to leverage this proven operational and scientific expertise to build additional platforms in the biopharmaceutical space.
Facts compiled by Executive Moves from publicly available news and press releases on 9 October 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you Martin Rose?
This is a Light profile, auto-generated from public news coverage. Claim it to verify your bio, add a photo and links, and control how your career is represented on Executive Moves.
Claim this profile →
